New drug shows promise in shrinking HER2+ colorectal tumors before surgery

NCT ID NCT07405476

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Feb 17, 2026 · Last updated May 13, 2026 · Updated 14 times

Summary

This study tests a drug called zanidatamab given before surgery for people with HER2-positive colorectal cancer. The drug targets cancer cells to help shrink tumors and improve treatment results. About 38 adults with early-stage colon or rectal cancer will take part to see if this approach leads to better outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Emory Decatur Hospital
RECRUITING

Decatur, Georgia, 30033, United States
Emory Saint Joseph's Hospital
RECRUITING

Atlanta, Georgia, 30342, United States
Emory University Hospital
RECRUITING

Atlanta, Georgia, 30322, United States

Contact Email: •••••@•••••

Contact
Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States

Conditions

Explore the condition pages connected to this study.